Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-1201 to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
NCT05936229Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon beta-1a in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Fred Hutchinson Cancer Center. Planned start Apr 2025; status: withdrawn.
02
Drugs
interferon beta-1a
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT05936229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936229.